Laboratory of Pharmaceutical Engineering, EA 4267, University of Franche-Comté, Besançon, France.
Curr Drug Deliv. 2013 Feb;10(1):9-17. doi: 10.2174/1567201811310010004.
Dose limitations in therapy induced by adverse effects due to unselective drug availability are a common problem. One prominent example for this dilemma are inflammatory diseases of the gastrointestinal tract. The challenge for drug delivery systems in the therapy of these diseases is the delivery of the active ingredient to the site of inflammation. Colloidal carriers allow to improve delivery of drugs to the site of action and appear promising to overcome this general therapeutic drawback. Here we focus on nanocarrier-based drug delivery strategies for the treatment of common inflammatory disorders like inflammatory bowel disease and gastric ulcer.
由于药物非选择性分布导致不良反应而限制治疗剂量是一个常见的问题。胃肠道炎性疾病就是一个突出的例子。这些疾病的药物输送系统面临的挑战是将活性成分递送到炎症部位。胶体载体可以改善药物向作用部位的输送，有望克服这一普遍的治疗缺陷。本文主要聚焦于基于纳米载体的药物传递策略，用于治疗常见的炎性疾病，如炎症性肠病和胃溃疡。
